Fresh analysis suggests that patients who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end conventional diet and exercise plans.
Research printed in a leading medical journal points out that while obese people often shed a large proportion of their body weight while on the medication, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using these treatments should be aware of the danger of rapid rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass within about 18 months.
Weighing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of these new drugs with other pills.
The team note that people who shed pounds through diet and exercise generally experience a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Experts suggest the mode of action of the jabs accounts for the accelerated weight return.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."
A Chronic Condition?
Medical guidelines suggest the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, due to the high risk of relapse, the therapy should be considered life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," similar to managing diseases like high blood pressure.
User Testimonies
Users who have come off the jabs explain a sudden resurgence of cravings.
"It felt as if a switch that goes on and you become ravenous," said an individual.
The struggle is worsened if patients have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Interest
Figures suggest that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, experts caution that while these medications are powerful tools for shedding pounds, they are not a standalone fix and long-term success hinges on combined behavioural support.
